Iterum Therapeutics Reports First Quarter 2020 Financial Results
May 14, 2020 06:45 ET
|
Iterum Therapeutics plc
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors -- DUBLIN,...
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)
March 31, 2020 07:00 ET
|
Iterum Therapeutics plc
Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO,...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
March 12, 2020 06:45 ET
|
Iterum Therapeutics plc
--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
Iterum Therapeutics Reports Second Quarter 2019 Financial Results
August 14, 2019 07:00 ET
|
Iterum Therapeutics plc
--Phase 3 Topline Data anticipated in the fourth quarter-- -- NDA filings expected in first quarter of 2020-- DUBLIN, Ireland and CHICAGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
May 02, 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Provides Corporate and Product Pipeline Update
January 03, 2019 07:30 ET
|
Otonomy, Inc.
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) --...
Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 05, 2018 16:12 ET
|
Otonomy, Inc.
Conference call and webcast today at 4:30 p.m. EST Conference call will include review of OTO-413 program selected as "Hot Topic" at Society for Neuroscience Annual Meeting SAN DIEGO, Nov. 05, 2018...
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
October 05, 2018 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Iterum to Present at Cantor Fitzgerald Global Healthcare Conference
September 25, 2018 16:05 ET
|
Iterum Therapeutics plc
DUBLIN and CHICAGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens,...
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
September 18, 2018 08:00 ET
|
Iterum Therapeutics plc
Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product candidate sulopenem Potential to be first and only oral and IV penem antibiotic available...